Business, energy, technology, markets and global industry news from Business News Today

Zai Lab

PharmaDeviceNews Zai Lab
A representative image illustrating LB Pharmaceuticals’ LB-102 schizophrenia research as the pivotal NOVA-2 Phase 3 program advances toward an accelerated first-half 2027 readout.
Pharma & Biotech

Zai Lab just secured reimbursement for two growth medicines. Can 2027 reverse its revenue decline?

Zai Lab gains China reimbursement listings for KarXT and VYVGART Hytrulo from January 2027. See how access could reshape product growth.

Read More
Representative image: A dermatologist examines chronic hand eczema as LEO Pharma’s ESCD 2026 data highlight the condition’s impact on work, school participation and daily life.
Pharma & Biotech

One antibody could target both eczema inflammation and itching. Zai Lab’s first human results are coming

Zai Lab will present initial Phase 1 data for ZL-1503 at ACAAI 2026 on November 13, evaluating safety, pharmacokinetics and inflammatory biomarkers in healthy volunteers. The investigational bispecific antibody targets IL-13 and IL-31 receptor signaling, but clinical efficacy in patients with atopic dermatitis remains unreported.

Read More
Zai Lab prepares to report second-quarter 2026 results as investors assess revenue recovery, new China product launches and progress across its oncology and neuroscience pipeline. Representative image.
Pharma & Biotech

Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work

Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.

Read More
Pharma & Biotech

Why EMA orphan status gives Zai Lab’s zoci more than a regulatory credibility boost

Find out how Zai Lab’s zocilurtatug pelitecan could reshape DLL3-targeted cancer therapy as development risks remain.

Read More
Representative image of an atopic dermatitis drug development concept, illustrating how Zai Lab’s ZL-1503 is being positioned to target itch and inflammation pathways in early-stage immunology research.
Pharma & Biotech

Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?

Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.

Read More
Representative image of Zai Lab’s zocilurtatug pelitecan story at AACR 2026, highlighting its potential impact on small cell lung cancer brain metastases and neuroendocrine carcinomas.
Pharma & Biotech

AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?

Read how Zai Lab’s zocilurtatug pelitecan posted strong AACR 2026 data in SCLC brain metastases and NECs, and what it could change next.

Read More
Pharma & Biotech

How Boehringer Ingelheim and Zai Lab are advancing a two-pronged DLL3 attack in SCLC

Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.

Read More
Pharma & Biotech

NMPA clears Zai Lab’s COBENFY, rewriting the schizophrenia treatment playbook

Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.

Read More